Atea Pharmaceuticals, Inc.

Ladies and gentlemen, thank you for standing by. Welcome to Attea Pharmaceuticals' first quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If you should require operator assistance during the conference, please press star zero on your telephone keypad. I will now turn it over to the Attea management team. Please go ahead.

Hi, thank you, Operator. Good afternoon, everyone, and welcome to Atea Pharmaceuticals' first quarter 2026 financial results and business update conference call. Earlier today, we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the slides that we'll be reviewing today by visiting the investor section of our website at ir.ateafarma.com. With me today from Atea are our Chief Executive Officer and Founder, Dr. Jean-Pierre Samadosi, Chief Development Officer, Dr. Janet Hammond, Chief Commercial Officer, John Vavrica, Chief Medical Officer, Dr. Arantahorga, and Chief Financial Officer and Executive Vice President of Legal, Andrea Corcoran, who will all be available for the Q&A portion of today's call. Before we begin the call, and as outlined on slide two, I would like to remind you that today's discussion will contain forward-looking statements that involve risk and uncertainties. These risk and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we encourage you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Jean-Pierre.

Thank you, Joné. Good afternoon, everyone, and thank you for joining us. I will begin on slide three. With two pivotal Phase III top-line readouts for our global Phase III HCV program ahead of us, 2026 will be a catalyst-rich year for Apteia. We remain on track and are very encouraged by the substantial progress our team continues to achieve. We completed patient enrollment for CBR, our North American trial, late last year with over 880 patients who are representative of the genotypes and demographics in North America. Proceed forward our ex-North America trial. I'm pleased to share today that we have completed enrollment for 95% of the cirrhotic and non-cirrhotic patients and anticipate to complete enrollment next month's schedule. Currently, enrollment is only open to the less prevalent genotypes such as four, five, and six, which will allow us to support a broad label. This set up two important phase three milestones. We expect top line data from CBI in mid-year, as we have reported before, and top line data from C4 around year end. Late last year, we expanded our anti-viral hepatitis pipeline to address a major unmet medical need for immunocompromised patients living with chronic hepatitis E infection, a liver disease for which there is currently no approved therapy. If left untreated in this at-risk population, it can rapidly progress to cirrhosis within only three to five years. We have completed cta enabling studies for 8587 our lead product candidate and we anticipate to initiate a first in human study media initial results were presented in february at koi 2026 and additional data will be presented at easel later this month to support AT587 as a potential first-in-class inhibitor against hepatitis E infection. I will review this exciting program and our clinical plan for a first-in-human study later in this presentation. Importantly, with $256 million of cash, cash equivalent and marketable securities as of March 31st, 2026, we are strong financial position to execute and complete our Phase III HCV program and advance our new HEV development program. We anticipate our cash flow runway remaining through 2027. With that, I will now turn the call over to Janet to review the profile of our regimen.